Lindsay A. Rosenwald, M.D.

Executive Chairman and Interim Chief Executive Officer

Dr. Lindsay Rosenwald has served as the Executive Chairman and Interim Chief Executive Officer of Oncogenuity since its inception in May 2020. Over the last 25 years, Dr. Rosenwald has been an active biotechnology entrepreneur, founding and recapitalizing numerous public and private life sciences companies. He has been a member of the Board of Directors of Fortress Biotech since October 2009, as well as Chairman, President, and Chief Executive Officer since December 2013. He also serves as a director of Mustang Bio, Inc., Chairman of the Board of Directors of Avenue Therapeutics, Inc., and a director of Checkpoint Therapeutics, Inc. From November 2014 to August 2015, Dr. Rosenwald served as Interim President and Chief Executive Officer of Checkpoint Therapeutics, Inc., and from 1991 to 2008, Dr. Rosenwald served as the Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received his Bachelor of Science in Finance from Pennsylvania State University and his Doctor of Medicine from Temple University School of Medicine.

Michael S. Weiss

Director

Michael Weiss has served as a member of the Board of Directors of Oncogenuity since its inception in May 2020. He has also served as Fortress Biotech’s Executive Vice Chairman, Strategic Development since February 2014. Mr. Weiss also serves as Executive Chairman of the Board of Directors of Mustang Bio, Inc. and Chairman of the Board of Directors of Checkpoint Therapeutics, Inc. Since December 2011, Mr. Weiss has served in multiple capacities at TG Therapeutics, Inc. and is currently its Executive Chairman, Chief Executive Officer, and President. He began his professional career as a lawyer with Cravath, Swaine & Moore LLP. In 1999, Mr. Weiss founded Access Oncology which was acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004. Following the merger, Mr. Weiss remained as Chief Executive Officer of Keryx. Mr. Weiss earned his Doctor of Laws from Columbia Law School and his Bachelor of Science in Finance from the University at Albany.